These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1083 related articles for article (PubMed ID: 33517367)

  • 21. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of novel inhibitors of SARS-CoV-2 main protease (M
    Verma S; Patel CN; Chandra M
    J Comput Chem; 2021 Oct; 42(26):1861-1872. PubMed ID: 34287986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.
    Varadharajan V; Arumugam GS; Shanmugam S
    J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
    Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2.
    Mahmud S; Uddin MAR; Zaman M; Sujon KM; Rahman ME; Shehab MN; Islam A; Alom MW; Amin A; Akash AS; Saleh MA
    J Biomol Struct Dyn; 2021 Oct; 39(16):6281-6289. PubMed ID: 32705962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of alkaloids from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Mol Struct; 2021 Apr; 1229():129489. PubMed ID: 33100380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
    Purohit P; Dash JJ; Muya JT; Meher BR
    J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depicting the inhibitory potential of polyphenols from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
    Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular dynamics and absolute binding free energy studies of piperine derivatives as potential inhibitors of SARS-CoV-2 main protease.
    Amperayani KR; Varadhi G; Oruganti B; Parimi UD
    J Biomol Struct Dyn; 2023; 41(23):13696-13706. PubMed ID: 36995111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual Screening of
    Miandad K; Ullah A; Bashir K; Khan S; Abideen SA; Shaker B; Alharbi M; Alshammari A; Ali M; Haleem A; Ahmad S
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36432204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
    Refaey RH; El-Ashrey MK; Nissan YM
    Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.
    Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B
    J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
    Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
    Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease.
    Basu S; Veeraraghavan B; Ramaiah S; Anbarasu A
    Microb Pathog; 2020 Dec; 149():104546. PubMed ID: 33011363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.